Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;36(1):31-47.
doi: 10.1177/0272989X15579173. Epub 2015 Apr 15.

Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries

Affiliations

Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries

Christian E H Boehler et al. Med Decis Making. 2016 Jan.

Abstract

Background: Published cost-effectiveness estimates can vary considerably, both within and between countries. Despite extensive discussion, little is known empirically about factors relating to these variations.

Objectives: To use multilevel statistical modeling to integrate cost-effectiveness estimates from published economic evaluations to investigate potential causes of variation.

Methods: Cost-effectiveness studies of statins for cardiovascular disease prevention were identified by systematic review. Estimates of incremental costs and effects were extracted from reported base case, sensitivity, and subgroup analyses, with estimates grouped in studies and in countries. Three bivariate models were developed: a cross-classified model to accommodate data from multinational studies, a hierarchical model with multinational data allocated to a single category at country level, and a hierarchical model excluding multinational data. Covariates at different levels were drawn from a long list of factors suggested in the literature.

Results: We found 67 studies reporting 2094 cost-effectiveness estimates relating to 23 countries (6 studies reporting for more than 1 country). Data and study-level covariates included patient characteristics, intervention and comparator cost, and some study methods (e.g., discount rates and time horizon). After adjusting for these factors, the proportion of variation attributable to countries was negligible in the cross-classified model but moderate in the hierarchical models (14%-19% of total variance). Country-level variables that improved the fit of the hierarchical models included measures of income and health care finance, health care resources, and population risks.

Conclusions: Our analysis suggested that variability in published cost-effectiveness estimates is related more to differences in study methods than to differences in national context. Multinational studies were associated with much lower country-level variation than single-country studies. These findings are for a single clinical question and may be atypical.

Keywords: cardiovascular disease; economic evaluation; exchangeability; multilevel statistical modeling; statins; transferability.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests, including any financial, personal, or other relationship with other people or organizations within 3 years of beginning this study.

Figures

Figure 1
Figure 1
Developing multilevel models to reflect complex structures in a data set of published cost-effectiveness estimates (model descriptions and unit diagrams).
Figure 2
Figure 2
Search algorithm (PRISMA flowchart).
Figure 3
Figure 3
Venn diagram illustrating the nature of the economic evaluation data.
Figure 4
Figure 4
Forest plots of incremental costs and incremental effects on country level.

Similar articles

Cited by

References

    1. Anderson R. Systematic reviews of economic evaluations: utility or futility. Health Econ. 2010;19(3):350–64. - PubMed
    1. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: URL: www.cochrane-handbook.org.
    1. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66(2):140–50. - PubMed
    1. Anderson R, Shemilt I. Chapter 3: the role of economic perspectives and evidence in systematic review. In: Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, eds. Evidence-Based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice. Oxford, UK: Wiley-Blackwell; 2010.
    1. Shemilt I, McDaid D, Marsh K, et al. , on behalf of the Campbell and Cochrane Economics Methods Group. Issues in the incorporation of economic perspectives and evidence into Cochrane reviews. Syst Rev. 2013;2:83. - PMC - PubMed

MeSH terms

Substances